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Abstract: Since the mid-1990s, investigational sites in the countries of Central and Eastern 
Europe (CEE) have been increasingly utilized by pharmaceutical companies because of their 
high productivity in terms of patient enrolment into clinical trials. Based on the FDA’s pub-
licly accessible Clinical Investigator Inspection List, we present an analysis of findings and 
outcome classifications from FDA inspections during Investigational New Drug (IND) studies 
and compare the results for the CEE region to those from Western European countries and the 
USA. Data from all 5531 FDA clinical trials inspections that occurred between 1994 (when the 
FDA first performed inspections in CEE) and the end of 2010 were entered into the database for 
comparative analysis. Of these, 4865 routine data audit (DA) inspections were analyzed: 401 
from clinical trials performed in Western Europe, 230 in CEE, 3858 in the USA, and 376 in 
other countries. The average number of deficiencies per inspection ranged between 0.99 for CEE 
and 1.97 in Western Europe. No deficiencies were noted during 16.6%, 39.0%, and 21.5% of 
the inspections in Western Europe, CEE and USA, respectively. The percentages of inspections 
after which no follow-up action was indicated were 36.9% for Western Europe, 55.7% for CEE, 
and 44.3% for US sites. CEE was also the region with the lowest percentage of inspections that 
required official or voluntary action. On the basis of FDA inspection data, the high productivity 
of CEE sites appears to be accompanied by regulatory compliance as well as by data quality 
standards that are not inferior to those in Western regions.
Keywords: clinical trials, inspection, Central and Eastern Europe (CEE), data quality, 
deficiencies
Introduction
After the fall of the “Iron Curtain” and the disintegration of the Soviet Union during 
the late 1980s and the early 1990s, the countries of Central and Eastern Europe (CEE) 
with their total population of about 340 million people (including the European part 
of Russia), have become increasingly attractive for international pharmaceutical com-
panies as sites for the conduct of clinical trials. An abundance of well educated, often 
treatment-naïve patients who are eager to participate in clinical trials that may offer 
otherwise unavailable treatment opportunities may contribute to this attractiveness. 
Further, the availability of numerous highly qualified and motivated clinical investiga-
tors without competing trials enhances enrollment success. Clinical research associates 
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and monitors are usually physicians in contradistinction to 
those found in other regions of the world.1
Many CEE countries still adhere to a public healthcare 
system organization similar to that of the Soviet Union. With 
respect to the requirements of clinical trials this includes the 
availability of comprehensive, often lifelong patient records, 
comparatively few, but large, specialized medical centers and 
a tight, mainly “vertical” referral system organized according 
to therapeutic hierarchies, with only minimal competition 
for patients between the centers. The availability of patients’ 
medical histories is also associated with lower screening 
failure and premature withdrawal rates.2 Furthermore, the 
CEE population in general tends to be less mobile than resi-
dents of Western countries, allowing for an easier long-term 
follow-up.3 Based on data from 50 international phase II 
and III clinical trials for which enrollment data per center 
and per month were analyzed, it has been estimated that the 
average site productivity (measured as patients enrolled per 
site and per month) in Russia, Ukraine, and the Balkans is 
more than twice that found in Western Europe and in the 
USA.2 Consequently the number of internationally sponsored 
clinical trials initiated in CEE countries has more than tripled 
between 2002 and 2007.4
In common, CEE and Western countries have tradi-
tionally required evidence-based medicine and research. 
Although not a part of the International Conference on 
Harmonization (ICH) region, CEE states adopted ICH-GCP 
(Good Clinical Practice) standards during the 1990s along 
with Western Europe and the USA.2 In 2004 the Baltic states, 
Bulgaria, the Czech Republic, Hungary, Poland, Romania, 
Slovakia and Slovenia joined the European Union (EU) and 
thus came under the jurisdiction of EU legislation and guid-
ance for clinical trials. The implementation of the EU Clinical 
Trials Directive5 and GCP Directive6 has informed intensive 
discussions of GCP principles among the stakeholders of 
clinical trials and improved their application to clinical trials 
conduct and subject protection.7
The accelerated recruitment found in CEE countries is 
advantageous for clinical trial sponsors only if accompanied 
by commensurate data quality and adherence to GCP. Herein 
we present an analysis of publicly accessible data compiled 
by the US Food and Drug Administration (FDA) during trial 
site inspections carried out in US Investigational New Drug 
(IND) studies.
Material and methods
The FDA’s Center for Drug Evaluation and Research (CDER) 
maintains a publicly accessible list of names, addresses, and 
other pertinent information gathered from GCP compliance 
inspections of clinical investigators who have performed 
studies in the context of a United States IND program since 
July 1977. The list is updated at quarterly intervals. The 
Clinical Investigator Inspection List (CLIIL) is available for 
download through the internet under http://www.fda.gov/
Drugs/InformationOnDrugs/ucm135198.htm. A searchable 
version is accessible under http://www.accessdata.fda.gov/
scripts/cder/CLIIL/index.cfm?fuseaction=Browse.Home 
(web link status of 10 May 2011).
Each investigator is identified by a unique investigator ID 
number. For each inspection, included are the start date and 
classification code that indicates the focus of the inspection 
whether “DA” [Data Audit – inspections for verification of 
study data], “FC” [For Cause – inspections for conduct of 
the study by the clinical investigator], and “OT” [Other]). 
Inspection results are classified according to one of the 
following three main categories:
NAI – No Action Indicated (no objectionable conditions 
or practices were found during the inspection);
VAI – Voluntary Action Indicated (objectionable con-
ditions were found, but do not justify further regulatory 
action; any corrective action is left to the investigator to 
take voluntarily);
OAI – Official Action Indicated (objectionable conditions 
were found and regulatory and/or administrative sanctions 
by FDA are indicated).
For the classification of observed findings, 22 deficiency 
codes are available that can be assigned to an inspection in 
any applicable combination.
The FDA began inspecting sites in the CEE region ini-
tially in 1994. Our analysis is based on completed   inspections 
in the FDA’s database from January 1, 1994 through 
  December 31, 2010. The analysis is restricted to DA inspec-
tions because no FC and OT inspections performed in any 
CEE country are present in the database. DA inspections 
represent inspections performed by the FDA as a part of the 
agency’s routine quality assurance measures and account 
for about 88% of all inspections performed since 1994. 
Inspections with   classification codes CANC (cancelled before 
start of inspection), MTF (case closed with memo to file), 
WASH (washout – no meaningful information obtained), or 
REF (reference), as well as database records without a clas-
sification code were excluded from the analyses.
Table 1 shows the regions and countries in which DA 
inspections were completed between 1994 and 2010.
The inspection data were analyzed using methods of 
descriptive data analysis. Outcome codes are grouped by 
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region of interest: the USA, Western Europe, Central and 
Eastern Europe, and all other countries from which inspec-
tion results were available.
Results
Inspections included into the analysis
The FDA’s database current through December 31, 2010 
records a total of 5531 inspections completed between 1994 
and 2010 inclusive. The number of inspections per full year 
ranged between 197 in 1994 and 411 in 2008. Figure 1 shows 
that between 300 and 400 inspections were completed 
  annually during 12 out of the 15 years from 1995 through 
2009, with no clear trend over time towards more or fewer 
inspections. The database of 31 December 2010 includes 
records referring to 174 inspections completed in 2010; 
more inspections started in 2010 and later completed may 
ultimately be included in subsequent database versions.
Of 5531 inspections performed between 1994 and 2010, 
4865 (88.0%) were data audits (DA) and were entered into 
our analyses.
Table 2 shows the number of DA inspections by region 
as well as the countries within each region in which at least 
10 inspections were conducted. Almost 80% of all DA 
inspections were performed in the USA. In Western Europe 
the countries with the highest number of DA inspections were 
the United Kingdom (97 inspections), Germany (70) and 
France (53). Together these countries accounted for 54.9% 
of the DA inspections performed in the Western European 
region between 1994 and 2010. Russia (75 inspections), 
Poland (59) and Hungary (21) were the countries where 
67.4% of the DA inspections conducted in Central and 
Eastern Europe were performed. Outside these regions the 
countries with the largest number of DA inspections were 
Canada (123 inspections) followed by Argentina (35) and 
South Africa (33).
Deficiencies
As shown in Table 3, deficiency codes were reported for 
3299 out of the 4865 DA inspections (67.8%) in the FDA’s 
database. These consist of those inspections during which 
deficiencies were found (deficiency codes 01 through 21) 
and not found (deficiency code 00). The percentages of 
Table 1 Regions and countries in which data audit inspections 
were performed between 1994 and 2010
Region Countries
Western Europe Austria, Belgium, Denmark, Ireland, 
Finland, France, Germany, Greece, 
Italy, the Netherlands, Norway, Spain, 
Sweden, Switzerland, United Kingdom
Central and Eastern Europe Bulgaria, Czech Republic, Croatia, 
Estonia, Hungary, Latvia, Lithuania, 
Poland, Romania, Russia, Slovenia, 
Serbia, Ukraine
North America Canada, USA
Central America Costa Rica, Guatemala, Mexico
South America Argentina, Brazil, Chile, Colombia, 
Ecuador, Paraguay, Peru
Africa Gabon, Ghana, Kenya (US Army), 
Malawi, Morocco, Nigeria, South Africa, 
Tanzania, Tunisia, Zambia
Middle East Egypt, Israel
Asia Bangladesh, China, Hong Kong, India, 
Japan, Korea, Malaysia, Philippines, 
Singapore, Taiwan, Thailand, Turkey
Australia and New Zealand Australia, New Zealand
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Figure 1 Number of inspections (any type) and data audits per year completed between 1994 and 2010.
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DA inspections during which no deficiencies were found 
(deficiency code 00) were 16.6% for Western Europe, 39.0% 
for the CEE region, 21.5% for US sites and 22.6% for other 
regions of the world. The average numbers of deficiencies 
(codes 01 through 21) per inspection were 1.99, 0.99, 1.59, 
and 1.49 for Western Europe, CEE, the USA, and for other 
regions of the world, respectively.
The five most frequently reported deficiencies in the 
total sample and in each region examined individually were 
failure to follow the investigational plan (code 05, noted 
in 51.4% of all DA inspections for which deficiency codes 
were reported), inadequate or inaccurate records (code 06, 
38.9%), inadequate informed consent form (code 03, 18.6%), 
inadequate drug accountability (code 04, 14.8%), and failure 
to report adverse drug reactions (code 16, 12.2%). Together 
these five deficiency codes account for 84.6% of all deficien-
cies uncovered at US sites (3483 of 4119 deficiencies) and 
for 89.1% of all deficiencies at non-US sites (998 of 1120).
When comparing the percentage of inspections with 
deficiencies of a certain kind in Western European countries 
and in the CEE region, 12 of the 20 codes 01 through 21 showed 
higher deficiency rates in inspections conducted in Western 
Europe whereas 2 showed higher rates in the CEE region. For 
6 codes (03, 04, 05, 06, 16, 18), the differences exceeded 5% 
in favor of CEE, the larger differences occurring for   “Failure 
to follow the investigational plan” (05; rate difference: 35.4%), 
“Inadequate informed consent form” (03; 14.5%) and “Inad-
equate and inaccurate records” (06; 11.4%).
The overall deficiency rate of DA inspections at US sites 
was lower than in Western Europe and higher than in the CEE 
region. Rate differences in favor of CEE were determined for 
16 out of the 18 codes indicating the presence of deficiencies 
whereas 2 codes showed lower rates for US sites. For five 
codes (03, 04, 05, 16, 18), the deficiency rate difference in 
favor of CEE exceeded 5% with the larger differences for 
“Failure to follow the investigational plan” (code 05, rate 
difference 19.6%), “Inadequate informed consent form” (03; 
13.6%), and “Other” (18; 6.9%).
Indicated action
Of the 4865 DA inspections assessed, 44.2% required 
no action and in 53.5%, voluntary action with or without 
requested response was indicated (Table 4). In 2.3% of the 
inspections, inspectors recommended official action with 
regulatory and/or administrative sanctions by the FDA.
Among the regions presented in Table 4, Western Europe 
showed the highest percentage of inspections followed by 
initiation of official action (4.5%) and the lowest percent-
age of inspections where no action was required (36.9%). 
In contrast, less than 1% of the cases in the CEE region 
were classified as OAI inspections and more than 55% of 
the inspections indicated no further action. The difference 
between the inspection outcome classifications (NAI/VAI/
OAI) in Western Europe and the CEE region was descrip-
tively significant (two-sided χ2-test, P , 0.001).
Warning letters were issued as a result of the inspection 
(classification code OAIW) in 4 cases in the USA (0.1% of 
all inspections at US sites) and after 1 inspection at a CEE 
site (0.4%).
Discussion
In a paper published in 2004, Platonov and Varshavsky 
analyzed the FDA’s inspections database from 1994 to 2004, 
with a total of 3178 inspections performed worldwide.8 Their 
results showed the percentage of inspections where no action 
was indicated (NAI) was 32%, 49% and 38% for Western 
Table 2 Number (%) of data audit inspections by region, as well 
as countries with at least 10 inspections between 1994 and 2010
Region/country Inspections* %*
Western Europe 401 8.2%
  Austria 10 0.2%
  Belgium 26 0.5%
  Denmark 17 0.3%
  Finland 13 0.3%
  France 53 1.1%
  Germany 70 1.4%
  Italy 39 0.8%
  The Netherlands 22 0.5%
  Spain 21 0.4%
  Sweden 20 0.4%
  United Kingdom 97 2.0%
Central and Eastern Europe 230 4.7%
  Czech Republic 15 0.3%
  Croatia 14 0.3%
  Hungary 21 0.4%
  Poland 59 1.2%
  Russia 75 1.5%
  Ukraine 11 0.2%
North America 3981 81.8%
  Canada 123 2.5%
  USA 3858 79.3%
Other 253 5.2%
  Mexico 21 0.4%
  Argentina 35 0.7%
  Brazil 24 0.5%
  South Africa 33 0.7%
  China 13 0.3%
  India 18 0.4%
Total inspections 4865 100.0%
Note: *Numbers and percentages for countries do not add up to numbers and 
percentages for regions or total number and percent, because countries with less 
than 10 inspections are not shown, although they are included in the analyses.
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Table 3 Number (%) of inspections by deficiencies, based on all data audit inspections for which any deficiency codes were reported 
(n = 3299)
Deficiency code Western Europe Central and Eastern Europe USA Other Total
00 = No deficiencies noted 48 
16.6%
60 
39.0%
557 
21.5%
60 
22.6%
725 
22.0%
01 = Records availability 2 
0.7%
2 
1.3%
30 
1.2%
5 
1.9%
39 
1.2%
02 = Failure to obtain and/or document subject consent 15 
5.2%
3 
1.9%
124 
4.8%
15 
5.7%
157 
4.8%
03 = Inadequate informed consent form 61 
21.0%
10 
6.5%
521 
20.1%
23 
8.7%
615 
18.6%
04 = Inadequate drug accountability 56 
19.3%
13 
8.4%
383 
14.8%
36 
13.6%
488 
14.8%
05 = Failure to follow investigational plan 193 
66.6%
48 
31.2%
1316 
50.8%
138 
52.1%
1695 
51.4%
06 = Inadequate and inaccurate records 148 
51.0%
61 
39.6%
950 
36.7%
123 
46.4%
1282 
38.9%
07 = Unapproved concomitant therapy 4 
1.4%
0 
0.0%
27 
1.0%
2 
0.8%
33 
1.0%
09 = Unapproved use of drug before IND submission 0 
0.0%
0 
0.0%
1 
0.0%
0 
0.0%
1 
0.0%
10 = Inappropriate delegation of authority 2 
0.7%
0 
0.0%
9 
0.3%
0 
0.0%
11 
0.3%
11 = Inappropriate use/commercialization of IND 0 
0.0%
0 
0.0%
3 
0.1%
0 
0.0%
3 
0.1%
12 = Failure to list additional investigators on 1572 1 
0.3%
0 
0.0%
10 
0.4%
3 
1.1%
14 
0.4%
13 = Subjects receiving simultaneous investigational drugs 0 
0.0%
0 
0.0%
3 
0.1%
0 
0.0%
3 
0.1%
14 = Failure to obtain or document IRB approval 2 
0.7%
0 
0.0%
56 
2.2%
6 
2.3%
64 
1.9%
15 =   Failure to notify IRB of changes, failure to submit 
progress reports
4 
1.4%
3 
1.9%
115 
4.4%
8 
3.0%
130 
3.9%
16 = Failure to report adverse drug reactions 47 
16.2%
9 
5.8%
313 
12.1%
32 
12.1%
401 
12.2%
17 = Submission of false information 0 
0.0%
0 
0.0%
5 
0.2%
0 
0.0%
5 
0.2%
18 = Other 35 
12.1%
4 
2.6%
246 
9.5%
5 
1.9%
290 
8.8%
19 =   Failure to supervise or personally conduct the clinical  
investigation*
1 
0.3%
0 
0.0%
4 
0.2%
0 
0.0%
5 
0.2%
20 =   Failure to protect the rights, safety, and welfare  
of subjects*
0 
0.0%
0 
0.0%
2 
0.1%
0 
0.0%
2 
0.1%
21 = Failure to permit FDA access to records* 0 
0.0%
0 
0.0%
1 
0.0%
0 
0.0%
1 
0.0%
Total 290 154 2590 265 3299
Note: *Codes 19 through 21 became effective only by October 1, 2005.
Europe, the CEE region and the USA compared respectively 
to 37%, 56% and 44% in our analysis through year 2010. 
Assuming that the FDA’s standards applied during inspec-
tions have not become less rigorous during the second half 
of the first decade of the 21st century, the increase in the 
percentage of NAI inspections may reflect GCP awareness 
and the successful implementation of quality control and 
quality assurance measures by investigational sites, sponsors 
and contract research organizations during recent years. In 
the CEE region, more than half of the FDA’s inspections 
did not require any follow-up action. The sequential find-
ings show a decrease in the percentage of inspections where 
official action was indicated in Western Europe from 7% in 
their report8 to 4.5% in our analysis while the percentages 
in CEE and the USA remained at low levels below 1% and 
at 2%, respectively.
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A comparison of indicated action by region suggests 
relative superiority for CEE over the USA and even more 
so over Western Europe. The rate difference for NAI was 
17% in Platonov’s and Varshavsky’s report8 and 19% in our 
analysis. These observations are paralleled by the results of 
the analysis of deficiency codes in which the percentage of 
inspections with no deficiencies in the CEE region (39.0%) 
was more than twice as high as in Western Europe (16.6%) 
and almost twice that of the USA (21.5%).
It is noteworthy that the top five deficiency codes found 
in DA inspections (failure to follow the investigational 
plan, inadequate or inaccurate records, inadequate informed 
consent form, inadequate drug accountability, and failure to 
report adverse drug reactions) were the same in all regions 
in our analysis and that of Platonov and Varshavsky.8 On the 
other hand, proportionate differences between the regions are 
noted. The most frequent deficiency in all regions outside 
CEE was failure to follow the investigational plan; the most 
frequent finding in CEE sites was inadequate or inaccurate 
records. The percentage of inspections in CEE countries 
where inadequate or inaccurate records were an issue (39.6%) 
was still comparable with US sites (36.7%) and substantially 
lower than in Western Europe (51.0%) or in other regions 
of the world (46.4%).
A limitation of this type of numerical analysis is that the 
impact of these relative differences in deficiency type on 
overall data quality remains speculative, such as whether 
inadequate/inaccurate records has less impact than failure 
to follow investigational plan. Minor protocol deviations 
versus protocol violations, for example, could be a relevant 
distinction. Further, the FDA Clinical Investigator   Inspection 
List from which this data is drawn for comparison does 
not identify the particular trial reviewed for inspection nor 
how frequently a codified deficiency indentified during an 
inspection occurred during the trial.
Another limitation inherent in our analysis is that no data 
is available regarding how investigational sites at which DA 
inspections were performed were selected and whether the 
same quality management standards were applied during all 
inspections. Since regulatory requirements regarding quality 
standards in clinical trials as well as the FDA’s collective 
experience in conducting inspections have evolved over time, 
it is reasonable to consider that the standards applied by the 
inspectors during their work at a study site may not always 
have been exactly the same. On the other hand, we could not 
find any evidence that the FDA’s data may have been biased 
towards an application of stricter or more liberal standards 
in any particular region of the world where clinical trials in 
IND programs are conducted.
Further potentially confounding factors should raise cau-
tion in the interpretation of such raw numerical comparisons 
from the FDA data source. One cannot assure that the sites 
among the regions were comparable in terms of enrollment 
numbers for the inspected trials. While countries typically 
maintain data on relative proportion of clinical trial phases per-
formed within their sovereignties, we have not compared our 
designated regions on this level nor have we compared ratios 
of inspections in relation to clinical phase. Such differences 
could have an effect on the proper interpretation of the numeri-
cal comparisons. Higher complexity of a clinical protocol may 
create further risk for conduction error although, in general, 
trials performed in CEE that would come under scrutiny by the 
FDA are part of worldwide or multiregional studies.
Considering that warning letters sent by the FDA reflect 
serious breaches of GCP rules, the respective percentages of 
CEE countries (1/230; 0.4%) and the USA (4/3858; 0.1%), 
suggest a perspective that runs counter to the more general 
conclusions drawn from the reporting data comparisons. Yet, 
the absolute numbers of warning letters being very small, 
a comparison of percentages may exaggerate the apparent 
difference.
These limitations on our report are in some measure miti-
gated by the support of its conclusions found in the results 
of benchmarking analyses that compared the efficiency and 
productivity of investigator sites in different countries and 
regions. The number of queries generated per subject was 
used as an indicator of data quality in two independent stud-
ies based on multinational clinical trials.9,10 Both analyses 
showed that there were substantially fewer queries in CEE 
countries than in Western Europe or North America and 
Australia/New Zealand.
Despite these data from the FDA, media reports   suggest 
continued concern by clinicians in the West, perhaps more 
so in the USA, regarding the acceptance of data from the 
rest of the world including Eastern Europe. Part of this 
Table 4 Number (%) of inspections by indicated action
Western  
Europe
Central and  
Eastern Europe
USA Other Total
NAI 148 128 1711 164 2151
36.9% 55.7% 44.3% 43.6% 44.2%
VAI 235 100 2061 206 2602
58.6% 43.5% 53.4% 54.8% 53.5%
OAI 18 2 86 6 112
4.5% 0.9% 2.2% 1.6% 2.3%
Total 401 230 3858 376 4865
Abbreviations: NAI, no action indicated; VAI, voluntary action indicated; OAI, 
official action indicated.
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concern regarding data validity may simply arise from home 
bias as occurs with financial investing in diverse markets. 
  Nonetheless, fear remains that budgetary challenges constrain 
the FDA from auditing an adequate portion of clinical trial 
  participation,   especially abroad, amid its vast oversight duties 
in pharmaceutical   development, drug and device manufacturing 
and food safety. Even in 2011, nearly 80% of FDA clinical trial 
site audits occurred in the USA while the majority of enrollees 
in NDA submission clinical trials were ex-USA (Table 2).11
Any evidence-based search for validity is threatened 
when the amount of data is limited. Though moot, our 
report codifies the data available. Mitigating the residual 
uncertainties will require more time and data. In the world 
of multinational pharmaceutical companies attempting to 
satisfy global markets, clinicians everywhere face the same 
dilemma: most of the data submitted for registry approval 
is from somewhere else. Clinical scientists in the USA 
worry whether a drug that appears efficacious and safe 
in foreign subjects will perform as well in the American 
populace.12 It should bear some consolation to clinicians in 
the USA, a principality with epic diversity, that abundant 
East   European ancestry in the US population as a result of 
generations of immigration should mitigate the concerns over 
genetic differences in study populations.
Results of our analysis of FDA inspection findings sug-
gesting superior performance, as with any conclusions drawn 
from small data sets, may be regarded as more credible when 
accompanied by plausible explanations. The authors specu-
late that the recent Soviet history of more central political 
and economic control that encompasses the national health-
care system may render investigators more accustomed to 
surveillance and conformity so essential to quality control in 
the clinical trial setting. East European investigators readily 
acknowledge that the income earned in clinical trials has a 
positive impact on staff motivation and the financial health 
of their divisions. Loss of the economic, professional and 
social opportunities provided by participation in clinical trials 
through poor performance may be relatively more palpable 
in general than the impact on western investigators. The 
establishment of ICH GCP in the 1990s that opened Western 
regulatory authorities to East European data has allowed 
East European clinicians to connect more intimately with 
western colleagues and technology. The value of this colle-
giality still appears to play a major role in the motivation for 
East European sites to sustain quality assurance. Underlying 
this purpose, highly trained physicians typically continue 
to fill the roles of site clinical coordinators and contract 
research associates as well as the roles of investigators and 
subinvestigators. These strata of professionals may represent 
the key to the QA differences in Eastern Europe indicated by 
FDA inspection reporting. Lastly, as the later entrants into 
the process of new medical product clinical development, we 
suspect a natural desire by highly qualified Eastern European 
investigators to demonstrate noninferiority through extra 
effort expended on assuring clean data.
In conclusion, according to the FDA’s Clinical Investigator 
Inspection List, investigator site DA inspections in the CEE 
region led to fewer findings regarding protocol compliance 
and record keeping, and also reported fewer issues with 
informed consent documents and procedures, inadequate drug 
accountability and failure to report adverse drug reactions 
than inspections performed in Western Europe, the USA 
or other parts of the world. CEE was also the region with 
the lowest percentage of inspections that required official 
or voluntary action. While unresolved confounding factors 
relevant to regional comparisons of the FDA’s inspection 
reporting data may exist, the data at large suggests that the 
high productivity of CEE sites is accompanied by regulatory 
compliance and data quality standards that are not inferior to 
those in Western regions.
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Official Action Indicated – Warning Letter; OT, Other 
(Inspection); VAI, Voluntary Action Indicated; WASH, 
Washout (no meaningful information obtained).
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